Γ

SynBioBeta Speaker

Erin Kim

Erin Kim Consulting

Principal Owner

Erin Kim, JD is Principal Owner of Erin Kim Consulting, which provides strategic intelligence and operational support to founders, investors, and startup teams commercializing emerging technologies, particularly where they intersect with consumer products (including beauty and personal care, food and beverage). 



A veteran of the biotech industry, Erin was an early team member at Geltor and New Harvest, where she played key roles in establishing cellular agriculture, and the commercialization of the first animal-free, biodesigned ingredients for the global beauty and personal care, and food and nutrition markets. 



She is a highly sought after speaker, writer, and subject matter expert on commercial, marketing, and communications strategy for innovative products and technologies, and has provided insights for the Wall Street Journal, SynBioBeta, Beauty Independent, ZINE, EAT Forum, the Ellen MacArthur Foundation, and investment firms around the world. 



Erin holds a Juris Doctor from the University of Alberta, and a Bachelor of Arts from the University of British Columbia.

Sessions Featuring

Erin

This Year

Special Event

12:00 PM

-

1:15 PM

General

Signal, Story, and Substance: A CEO’s Playbook for the Next Era of Biology

The conversation would explore how leaders navigate the transition from breakthrough science to commercial reality. Rather than focusing on marketing tactics, the panel would examine the deeper challenge of narrative discipline as the industry moves from speculation to execution: how CEOs build credibility with investors, partners, and the public while still inspiring teams and markets to believe in long-term transformation.

Special Event

12:00 PM

-

1:15 PM

General

Signal, Story, and Substance: A CEO’s Playbook for the Next Era of Biology

The conversation would explore how leaders navigate the transition from breakthrough science to commercial reality. Rather than focusing on marketing tactics, the panel would examine the deeper challenge of narrative discipline as the industry moves from speculation to execution: how CEOs build credibility with investors, partners, and the public while still inspiring teams and markets to believe in long-term transformation.

TBD

Session lineup still growing

Featuring

Speaker Coming Soon

Fireside Chat

12:00 AM

-

8:30 AM

Human Health

From Cells to Patients: Solving the Scale Mismatch in Virtual Biology

Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?

Featuring

Speaker Coming Soon

Previous Speakers Include